Article contents
A Controlled Trial of Taractan in Chronic Schizophrenia
Published online by Cambridge University Press: 29 January 2018
Extract
The purpose of this trial was to evaluate the drug Taractan in the treatment of chronic schizophrenia.
Taractan (chlorprothixene) is chemically α-2-chloro-9-(w-dimethylamino propylidene)-thioxanthene. It is claimed to have neuroleptic and tranquillizing properties as well as thymoleptic activity. It is also claimed to be relatively free from side-effects. This property facilitated its use in a double-blind study.
- Type
- Research Article
- Information
- Copyright
- Copyright © Royal College of Psychiatrists, 1963
References
- 3
- Cited by
eLetters
No eLetters have been published for this article.